Disclosure: This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio provides standardized stem cell product platforms to enable rapid clinical and commercial translation. Although this article was not sponsored, BioInformant has a paid business relationship with Rooster Bio.
RoosterBio blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in decades-old science, that are holding the field back. [Read more…]
